Topic: psoriatic arthritis
Eli Lilly's newer drugs are pumping out sales, especially its lead growth driver Trulicity, a diabetes drug. So much so, the company hiked its 2018 guidance.
For the second straight week, there’s a new psoriatic arthritis drug on the block.
Eli Lilly’s Taltz officially has a new arena to challenge Novartis’ Cosentyx.
Novartis’ Cosentyx currently leads a crop of immunology meds from a who’s who of Big Pharma. And the company intends to keep it that way.
Eli Lilly is counting on psoriasis med Taltz to drive U.S. volume growth. But lately, that growth has stalled.
Novartis has already featured real patients in Cosentyx psoriasis ads. Now, as it features the med in psoriatic arthritis, it’s going a similar route.
With its latest DTC work for Stelara, J&J is pivoting to push for growth in Crohn's disease instead of psoriasis.
Boehringer Ingelheim has scored a key victory in a patent battle with AbbVie over Humira, the world's top-selling drug.
The ankylosing spondylitis and psoriatic arthritis markets are getting crowded, but Novartis now has long-term Cosentyx data that not all its rivals can boast.
Novartis’ Cosentyx and Celgene’s Otezla aren’t just battling it out in the psoriasis arena. As of early this year, they’re competing in psoriatic arthritis, too—and each drugmaker made its case this week with new data in that disease.